Now showing items 7-9 of 9

    • Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. 

      Seibert, Tyler M; Fan, Chun Chieh; Wang, Yunpeng; Zuber, Verena; Karunamuni, Roshan; Parsons, J Kellogg; Eeles, Rosalind A et al. (BMJ, 2018-01-10)
      Objectives: Prostate-specific-antigen (PSA) screening resulted in reduced prostate cancer (PCa) mortality in a large clinical trial, but due to many false positives and overdiagnosis of indolent disease, many guidelines ...
    • Pro-neural transcription factors as cancer markers 

      Vias, Maria; Massie, Charles Edward; East, Philip; Scott, Helen; Warren, Anne; Zhou, Zongxiang; Nikitin, Alexander Yu et al. (2008-05-19)
      Abstract Background The aberrant transcription in cancer of genes normally associated with embryonic tissue differentiation at various organ sites may be a hallmark of tumour progression. For example, neuroendocrine ...
    • Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. 

      Asim, Mohammad; Tarish, Firas; Zecchini, Heather I; Sanjiv, Kumar; Gelali, Eleni; Massie, Charles Edward; Baridi, Ajoeb et al. (Nature Publishing Group, 2017-08-29)
      Emerging data demonstrate homologous recombination (HR) defects in castration resistant prostate cancers, rendering these tumours sensitive to PARP inhibition. Here, we demonstrate a direct requirement for the androgen ...